Cambridge, UK, 3 April 2006 – BioProgress (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company is pleased to announce the launch of Ronflux strips, a novel dissolve-in-the-mouth product for the prevention of snoring, and a new range of oral caffeine strips, at Pharmagora 2006.

The products, which will be initially available in France, make use of BioProgress’ novel SOLULEAVES™ technology. This technology allows active ingredients, colours and flavours to be incorporated into a non-genetically modified, non-animal derived film, which dissolves in the mouth, releasing the active ingredients.

The caffeine strips are the first in a new range of products, designed to improve alertness and vitality. The Ronflux strips will tap into the market for medical devices for the treatment of snoring.

The products were launched this weekend (1 April) through BioProgress’ subsidiary Dexo S.A. at Pharmagora 2006, an annual French retail pharmacists’ trade show, this year based at the Paris Expo, Port de Versailles, Paris.

Richard Trevillion, CEO of BioProgress said: “We are pleased to be able to offer these in-the-mouth products that address important needs for improved wellbeing. The launch of two newly-formulated products so soon after the acquisition of Dexo is an excellent validation of the Company’s approach. The launch involved the combined effort of our development teams in Cambridge and Tampa, Florida, USA, our formulation capability, and the sales, marketing and licensing infrastructure, acquired and grown since the Dexo acquisition in January 2006.”

Ronflux is one of the brands that was acquired by BioProgress with the acquisition of Dexo. It is currently marketed as a nasal spray. The newly-formulated products are manufactured at the BioProgress group’s cGMP accredited facility based in Tampa.

BioProgress is currently developing a number of other reformulated products using a variety of the Group’s platform technologies, including TABWRAP™, SWOLLO™ and WAFERTAB™, and containing existing branded and generic formulations.

For further information please contact: 

BioProgress plc	+44 (0)1223 3944250
Richard Trevillion, Chief Executive Officer
Dan Farrow, Finance Director
Northbank Communications	+44 (0)207 886 8150
Sue Charles Katja Stout Gemma Bradley

About BioProgress plc:

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London’s AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™ polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com 

Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934.  To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may vary materially from the expectations contained in the forward-looking statements.  The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation.  Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company’s filings with the Securities and Exchange Commission.  The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.  This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice.  The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law.  Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. 

-ENDS-